- ≥99% by HPLC; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
Amycretin
Investigational unimolecular GLP-1 and amylin receptor co-agonist peptide
- FormLyophilized powder, sealed glass vial with flip-off seal
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Amycretin is an investigational peptide designed as a unimolecular co-agonist: a single molecule that engages both the GLP-1 receptor and the amylin receptor complex. The two pathways have historically been targeted separately — incretin agonists such as semaglutide on one side, amylin analogues such as cagrilintide on the other — and combination approaches have generally meant co-administering two peptides. Amycretin represents the alternative strategy of building both activities into one acylated peptide backbone.
Specifications
Identity
- Peptide class
- Acylated unimolecular GLP-1 receptor and amylin receptor co-agonist
Supply & purity
- Form
- Lyophilized powder, sealed glass vial with flip-off seal
- Purity
- ≥99% by HPLC; lot-matched COA available
- Available sizes
- 5 mg, 10 mg
- Solubility
- Bacteriostatic water; gentle swirling, no vortexing
Handling & storage
- Storage (lyophilized)
- −20 °C, sealed and protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light, used within the study window
Additional detail
- Molecular targets
- GLP-1 receptor; calcitonin receptor with RAMP subunits (amylin receptor complex)
- Design rationale
- Two appetite-regulating pathways engaged by one peptide rather than two co-administered agents
- Regulatory status
- Investigational; not approved for any indication in any jurisdiction
- Documentation
- Third-party HPLC purity and identity report per lot
Questions about Amycretin
What makes amycretin different from semaglutide or tirzepatide?
Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 agonist. Amycretin's second arm is amylin rather than another incretin: it engages the calcitonin receptor–RAMP complexes that mediate amylin signalling, alongside the GLP-1 receptor, within a single molecule.
Is amycretin an approved medicine?
No. Amycretin is an investigational compound in early-phase development. It is not approved by the FDA, EMA or any other regulator for any indication, and it is offered here strictly as a research chemical for laboratory use.
Why does the specification list omit a molecular formula?
We publish only values we can state with confidence. Full structural details for amycretin are not established in the public literature to the standard we require, so we list class, targets and status rather than printing a formula or sequence we cannot verify.
What documentation comes with each lot?
Every lot is third-party tested by HPLC for purity and identity, with a lot-matched certificate of analysis available on request. Retain the COA with your study records so the material characterised can be traced to the data generated from it.
How is it prepared for laboratory work?
The lyophilized powder is reconstituted with bacteriostatic water added slowly against the vial wall and swirled gently rather than shaken. Solutions are held at 2–8 °C and protected from light. We provide no dosing, administration or protocol guidance of any kind.
Can amycretin be used in people?
No. This is a research chemical supplied for laboratory use only. It is not a medicine, is not dispensed under prescription, has not been approved for any use, and is not intended for human or veterinary administration.
Related
